Life sciences · Preprint
arXiv · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Preprint.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Scientific discovery requires plausible designs spanning useful trade-offs among competing properties: a molecule with strong binding affinity, for example, may be difficult to synthesize. Pretrained generative models, e.g., flow and diffusion generators, provide a foundation for proposing such designs, but steering them toward high-quality, complementary trade-offs remains challenging. Inference-time search incurs high per-sample costs, while fine-tuning typically relies on fixed per-candidate rewards that do not capture how designs complement one another. We introduce Hypervolume Fine-Tuning (HVFT), which adapts a single pretrained generator to maximize the expected hypervolume of its samples while controlling departure from the pretrained distribution. Expected hypervolume jointly rewards candidate quality and collective trade-off coverage. Nonetheless, we show that it cannot be expressed as the expectation of a fixed per-candidate reward and therefore cannot be optimized directly with standard techniques. A key observation of this work is that its first variation corresponds to the expected marginal hypervolume contribution of a candidate, which yields a tractable adaptive reward via an unbiased estimator based on model samples. HVFT uses this reward to decompose the objective into a sequence of KL-proximal scalar-reward subproblems. We establish concavity, relative smoothness, and convergence guarantees for the resulting distributional procedure. Across therapeutic-peptide and molecular design tasks spanning discrete diffusion and continuous flow-matching models, HVFT achieves state-of-the-art expected hypervolume and trade-off coverage.